{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jindra PT"],"funding":["THERAKOS, Inc.","Children's Leukemia Research Association","GlaxoSmithKline","NHLBI NIH HHS","Caridian BCT","CellGenix, GmbH","Fresenius-Biotech North America, Inc.","HistoGenetics, Inc.","The Leukemia & Lymphoma Society","Kiadis Pharma","Soligenix, Inc.","Ariad","Otsuka America Pharmaceutical, Inc.","National Marrow Donor Program","The Medical College of Wisconsin","Swedish Orphan Biovitrum","Wellpoint, Inc.","Millennium: The Takeda Oncology Co.","Seattle Genetics","Celgene Corporation","Teva Neuroscience, Inc.","Gamida Cell Teva Joint Venture Ltd.","Sanofi","Be the Match Foundation","Milliman USA, Inc.","Optum Healthcare Solutions, Inc.","RemedyMD","Sigma-Tau Pharmaceuticals","Tarix Pharmaceuticals","StemCyte, A Global Cord Blood Therapeutics Co.","Stemsoft Software, Inc.","Office of Naval Research","National Cancer Institute (NCI)","Genentech, Inc.","Blue Cross and Blue Shield Association","Amgen, Inc.","Osiris Therapeutics, Inc.","NCI NIH HHS","Genzyme Corporation","Miltenyi Biotec, Inc.","Allos, Inc.","Buchanan Family Foundation","Merck & Co, Inc."],"pagination":["27-36"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4743880"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["Despite stringent procedures to secure the best HLA matching between donors and recipients, life-threatening complications continue to occur after hematopoietic stem cell transplantation (HSCT). Studying single nucleotide polymorphism (SNP) in genes encoding costimulatory molecules could help identify patients at risk for post-HSCT complications. In a stepwise approach we selected SNPs in key costimulatory molecules including CD274, CD40, CD154, CD28, and TNFSF4 and systematically analyzed their association with post-HSCT outcomes. Our discovery cohort analysis of 1157 HLA-A, -B, -C, -DRB1, and -DQB1 matched cases found that patients with donors homozygous for the C variant of rs10912564 in TNFSF4 (48%) had better disease-free survival (P = .029) and overall survival (P = .009) with less t"],"journal":["Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation"],"pubmed_title":["Analysis of a Genetic Polymorphism in the Costimulatory Molecule TNFSF4 with Hematopoietic Stem Cell Transplant Outcomes."],"pmcid":["PMC4743880"],"funding_grant_id":["5U01HL069294","N00014-13-1-0039","U10 HL069294","U24-CA76518","U24 CA076518","N00014-12-1-0142","U01 HL069294"],"pubmed_authors":["Milford E","Ricklefs SM","Spellman S","Haagenson M","Wang T","McDermott DH","Abdi R","Jindra PT","Kraft P","Porcella SF","Conway SE","Anzick SL"],"additional_accession":[]},"is_claimable":false,"name":"Analysis of a Genetic Polymorphism in the Costimulatory Molecule TNFSF4 with Hematopoietic Stem Cell Transplant Outcomes.","description":"Despite stringent procedures to secure the best HLA matching between donors and recipients, life-threatening complications continue to occur after hematopoietic stem cell transplantation (HSCT). Studying single nucleotide polymorphism (SNP) in genes encoding costimulatory molecules could help identify patients at risk for post-HSCT complications. In a stepwise approach we selected SNPs in key costimulatory molecules including CD274, CD40, CD154, CD28, and TNFSF4 and systematically analyzed their association with post-HSCT outcomes. Our discovery cohort analysis of 1157 HLA-A, -B, -C, -DRB1, and -DQB1 matched cases found that patients with donors homozygous for the C variant of rs10912564 in TNFSF4 (48%) had better disease-free survival (P = .029) and overall survival (P = .009) with less t","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Jan","modification":"2026-05-05T20:17:12.423Z","creation":"2019-03-27T02:08:35Z"},"accession":"S-EPMC4743880","cross_references":{"pubmed":["26348892"],"doi":["10.1016/j.bbmt.2015.08.037"]}}